Loading
An analysis of more than 50,000 thyroid nodules tested with Afirma's RNA classifier and its variant and fusion panel, showing how often a genomic change was found.
In 50,644 nodules, at least one genomic alteration was identified by the expanded Xpression Atlas panel in 44 per cent of Bethesda III or IV nodules that the classifier called suspicious and in 87 per cent of Bethesda VI aspirates.
RNA sequencing of a thyroid aspirate can also report the mutation or fusion behind a suspicious nodule.
Shares Afirma Genomic Sequencing Classifier, Thyroid nodule FNA, Bethesda cytology & molecular classifiers, RNA sequencing & expression profiling, Thyroid cancer.
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Biomarker, Thyroid cancer.
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Biomarker, Thyroid cancer.
Shares Afirma Genomic Sequencing Classifier, Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
Shares Afirma Genomic Sequencing Classifier, Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/